The object is to provide a means which enables a cancer immunotherapy for about30% of various types of cancer patients in Japan who express forkhead box M1 (FOXM1)at high levels, by identifying a FOXM1-derived peptide which can bind to HLA-A2to activate a human killer T-cell that can kill a cancer cell. Specifically disclosedis a peptide selected from the following items (A) and (B): (A) a peptide comprisingan amino acid sequence depicted in any one of SEQ ID NOs: 1 to 3； and (B) a peptidewhich has the substitution, deletion, insertion and/or addition of one, twoor several amino acid residues in a peptide comprising an amino acid sequencedepicted in any one of SEQ ID NOs: 1 to 3 and which has an activity of inducing a cytotoxic(killer) T-cell.
